Viral Capsid Development Market
Description
Size, Share & Trends Analysis Report By Type (Adenoviral, Lentiviral), By Application (Gene Therapy, Vaccine Development), By End-use (Academic & Research Institute, CROs & CMOs), By Region, And Segment Forecasts, 2026 - 2033
Viral Capsid Development Market Summary
The global viral capsid development market size was estimated at USD 314.3 million in 2025 and is projected to reach USD 684.5 million by 2033, growing at a CAGR of 10.36% from 2026 to 2033. Growth is driven by increasing demand for gene therapies, rising viral vector R&D, and advancements in capsid engineering, though high costs and manufacturing complexities may limit expansion.
Advancements in Synthetic Biology & AI-Driven Design
Advancements in synthetic biology, along with AI-powered design advancements, are accelerating the development process of viral capsid systems through enhanced development accuracy and increased developmental capacity. Scientists use directed evolution together with rational protein engineering to create custom vectors that deliver gene therapies with improved safety and better ability to reach specific body tissues.
The process of analyzing extensive databases enables artificial intelligence to discover the best sequences, which decreases the need for experiments while driving clinical development forward and increasing the requirements for superior capsid engineering methods. For instance, in November 2025, in the U.S., Latus Bio expanded its AI/ML strategy for AAV gene therapy, leveraging extensive in vivo capsid datasets and adding leading experts to accelerate capsid discovery, payload design, and targeted delivery in viral capsid development.
Global Viral Capsid Development Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global viral capsid development market report based on the type, application, end-use, and region.
Viral Capsid Development Market Summary
The global viral capsid development market size was estimated at USD 314.3 million in 2025 and is projected to reach USD 684.5 million by 2033, growing at a CAGR of 10.36% from 2026 to 2033. Growth is driven by increasing demand for gene therapies, rising viral vector R&D, and advancements in capsid engineering, though high costs and manufacturing complexities may limit expansion.
Advancements in Synthetic Biology & AI-Driven Design
Advancements in synthetic biology, along with AI-powered design advancements, are accelerating the development process of viral capsid systems through enhanced development accuracy and increased developmental capacity. Scientists use directed evolution together with rational protein engineering to create custom vectors that deliver gene therapies with improved safety and better ability to reach specific body tissues.
The process of analyzing extensive databases enables artificial intelligence to discover the best sequences, which decreases the need for experiments while driving clinical development forward and increasing the requirements for superior capsid engineering methods. For instance, in November 2025, in the U.S., Latus Bio expanded its AI/ML strategy for AAV gene therapy, leveraging extensive in vivo capsid datasets and adding leading experts to accelerate capsid discovery, payload design, and targeted delivery in viral capsid development.
Global Viral Capsid Development Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global viral capsid development market report based on the type, application, end-use, and region.
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Adeno-associated Virus (AAV) Capsids
- Adenoviral
- Lentiviral
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Gene Therapy
- Vaccine Development
- Cancer Therapy
- Others
- End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institute
- CROs & CMOs
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
120 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. End Use
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Research
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Expansion of Gene Therapy Clinical Pipeline
- 3.2.1.2. Increasing Demand for Tissue-Specific and Targeted Delivery Systems
- 3.2.1.3. Growing Outsourcing to Specialized CROs and CDMOs
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Development and Production Costs
- 3.2.2.2. Limited Scalability of Advanced Capsid Platforms
- 3.2.3. Market Opportunity Analysis
- 3.2.3.1. Integration of AI and Machine Learning in Capsid Engineering
- 3.2.3.2. Emerging Applications in Oncology and Rare Diseases
- 3.2.4. Market Challenge Analysis
- 3.2.4.1. Manufacturing Complexity and Process Variability
- 3.2.4.2. Limited Standardization in Capsid Characterization Methods
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- Chapter 4. Viral Capsid Development Market: Type Business Analysis
- 4.1. Type Segment Dashboard
- 4.2. Global Viral Capsid Development Market Type Movement Analysis
- 4.3. Global Viral Capsid Development Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 4.4. Adeno-Associated Virus (AAV) Capsids
- 4.4.1. Global Adeno-Associated Virus (AAV) Capsids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Adenoviral
- 4.5.1. Global Adenoviral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Lentiviral
- 4.6.1. Global Lentiviral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Others
- 4.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Viral Capsid Development Market: Application Business Analysis
- 5.1. Application Segment Dashboard
- 5.2. Global Viral Capsid Development Market Application, Movement Analysis
- 5.3. Global Viral Capsid Development Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 5.4. Gene Therapy
- 5.4.1. Global Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Vaccine Development
- 5.5.1. Global Vaccine Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Cancer Therapy
- 5.6.1. Global Cancer Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Others
- 5.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Viral Capsid Development Market: End Use Business Analysis
- 6.1. End Use Segment Dashboard
- 6.2. Global Viral Capsid Development Market End Use Movement Analysis
- 6.3. Global Viral Capsid Development Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 6.4. Pharmaceutical and Biotechnology Companies
- 6.4.1. Global Pharmaceutical and Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Academic and Research Institute
- 6.5.1. Global Academic and Research Institute Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. CROs & CMOs
- 6.6.1. Global CROs & CMOs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Viral Capsid Development Market: Regional Estimates & Trend Analysis by Type, Application, & End Use.
- 7.1. Regional Dashboard
- 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
- 7.3. North America
- 7.3.1. North America Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. U.S. Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Canada
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. Canada Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Regulatory Framework
- 7.3.4.4. Mexico Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Europe
- 7.4.1. Europe Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. UK
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. UK Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Germany
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Germany Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. France
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. France Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.5. Italy
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Competitive Scenario
- 7.4.5.3. Regulatory Framework
- 7.4.5.4. Italy Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.6. Spain
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Competitive Scenario
- 7.4.6.3. Regulatory Framework
- 7.4.6.4. Spain Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.7. Denmark
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Competitive Scenario
- 7.4.7.3. Regulatory Framework
- 7.4.7.4. Denmark Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.8. Sweden
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Competitive Scenario
- 7.4.8.3. Regulatory Framework
- 7.4.8.4. Sweden Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.9. Norway
- 7.4.9.1. Key Country Dynamics
- 7.4.9.2. Competitive Scenario
- 7.4.9.3. Regulatory Framework
- 7.4.9.4. Norway Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Japan
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Japan Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. China
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. China Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. India
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. India Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Australia
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Australia Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Thailand
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Thailand Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. South Korea
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. South Korea Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Latin America
- 7.6.1. Latin America Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Brazil
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Brazil Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Argentina Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. MEA
- 7.7.1. MEA Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. South Africa Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Saudi Arabia
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Saudi Arabia Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.4. UAE
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Competitive Scenario
- 7.7.4.3. Regulatory Framework
- 7.7.4.4. UAE Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.5. Kuwait
- 7.7.5.1. Key Country Dynamics
- 7.7.5.2. Competitive Scenario
- 7.7.5.3. Regulatory Framework
- 7.7.5.4. Kuwait Viral Capsid Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Share/ Position Analysis, 2025
- 8.4. Participant’s Overview
- 8.4.1. PackGene Biotech Inc.
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Sartorius AG
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Revvity
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. VectorBuilder
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. AAVnerGene
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. AskBio Inc.
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Voyager Therapeutics
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Vigene Biosciences
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Capsigen
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. uniQure N.V.
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
